InVitria

Lentiviral vectors can lose infectious titer during downstream processing steps like TFF, sterile filtration, freeze-thaw, and process holds.
InVitria’s latest poster shows how Optibumin® 25 recombinant human serum albumin supported LVV stability and recovery across multiple DSP stress conditions.
The data was presented at ASGCT 2026 in Boston.
Download the poster: https://hubs.ly/Q04k7wN60

Recombinant Albumin Enhances Lentiviral Vector Stability During Downstream Processing InVitria: Recombinant, Animal-Free Cell Culture Media & Supplements InVitria is a global leader in blood-free, chemically defined media & supplements that support the approval of life-changing medicines.

Join InVitria at ASGCT 2026 in Boston to see new data on reduced-DMSO cryopreservation using recombinant albumin.

Mark Stathos, PhD, Applications Scientist at InVitria, will present Poster #2182:
“Enhanced Cryopreservation of Therapeutically Relevant Cells: Superior Performance of Recombinant Albumin and Its Role in Reducing DMSO Dependency.”

The poster highlights post-thaw performance data across T cells, MSCs, and iPSCs, including viability, expansion, apoptosis, and pluripotency outcomes under reduced-DMSO conditions.

Stop by Poster #2182 to discuss the data with our team.

Join InVitria at ASGCT 2026 today as Mark Stathos, PhD presents new data on recombinant animal-free albumin for lentiviral vector manufacturing and downstream processing.

The presentation will highlight how recombinant albumin helped:
• Improve infectious lentiviral vector yields
• Preserve vector titers during sterile filtration
• Support downstream processing and final formulation workflows

📍 Room 162AB
🕓 Today at 4:45 PM
📍 Visit InVitria at Booth #909

Don't forget our POSTER # 2182 on Cryopreservation of Therapeutic Cells using LOWER DMSO!!!!!

Heading to ASGCT 2026? Stop by Booth #909 to meet the InVitria team and learn how recombinant, animal-origin-free proteins are supporting gene and cell therapy workflows.

We’ll also be presenting about how to enhancing infectious lentiviral vector yields.
Title: Recombinant Animal-Free Albumin Enhances Infectious Lentiviral Vector Yields By Stabilizing Viral Particles During Downstream Processing and Final Formulation.
Presented by Mark Stathos, PhD
📍May 12 at 4:45 PM | Room 162AB

And presenting a poster:
📍 #2182
Title: Enhanced Cryopreservation of Therapeutically Relevant Cells: Superior Performance of Recombinant Albumin and Its Role in Reducing DMSO Dependency

See how recombinant albumin can support:
• Reduced-DMSO cryopreservation
• Post-thaw recovery
• Cell viability and expansion
• More defined manufacturing workflows

Day 2 in Nashville and the booth has been the best seat in the house. 👋

After Scott's talk yesterday on the recombinant albumin journey, the questions kept coming — about Exbumin® for lyophilized formulations, Optibumin® 25 for closed-system GMP workflows, and what it really takes to move away from plasma-derived HSA.

These are our favorite kinds of conversations: real problems, real formulations, real timelines.

If you're at IPEC Excipient World, come find Scott, Elliott and Jake at Booth #328 — we're here through tomorrow. ☕️

What does it take for a novel excipient to become a standard?

At the Biologics Summit, Scott Deeter broke down the recombinant albumin journey, including:
• Stability and performance considerations
• Regulatory path and adoption barriers
• Real-world use in approved biologics

Relevant for teams working on formulation, process consistency, or risk reduction.
The talk will be posted soon. Visit https://hubs.ly/Q04fjN6H0 to receive it directly

InVitria is heading to ISCT Annual Meeting.

We’ll be onsite connecting with teams working on cell therapy development and manufacturing.

If you’re attending, plan to meet with
Marcus Curl, VP of Product Applications, and
Jake Hanks, Director of Business Development.

They’ll be discussing how animal-origin-free, chemically defined proteins support:

Consistent cell expansion
Scalable manufacturing
Reduced variability across workflows

If you’re working on process development or scale-up, reach out ahead of the meeting to connect.

Recombinant albumin is already used in approved biologics.

At IPEC Excipient World 2026, we’re sharing how Exbumin® and Optibumin® 25 support:
• formulation stability
• lot-to-lot consistency
• scalable GMP manufacturing

See the full announcement: https://hubs.ly/Q04dQB6L0

InVitria Showcases Exbumin and Optibumin 25 at IPEC Excipient World: Biologics Summit InVitria: Recombinant, Animal-Free Cell Culture Media & Supplements InVitria is a global leader in blood-free, chemically defined media & supplements that support the approval of life-changing medicines.

Nashville, here we come! 🎸
The InVitria team is headed to Excipient World 2026 next week (May 4-6) at the Ga***rd Opryland Resort & Convention Center. This is the only U.S. event focused exclusively on excipients, and we're thrilled to be part of the conversation.
CEO Scott Deeter will be presenting "From Novel Excipient to Gold Standard: The Recombinant Albumin Journey" on May 4th. He'll be joined by Elliott Renft and Jacob Weber, PhD, who are ready to talk all things recombinant proteins and novel excipients.
👉 Find us at Booth 328
👉 Explore our excipient resources and comparison info: https://hubs.ly/Q04cMxxb0
See you in Nashville!

Today is World Laboratory Day.

Behind every dataset, publication, and therapeutic candidate is a lab making it happen.

At InVitria, we support that work with:

Animal-origin-free recombinant proteins
Consistent, defined materials
Scalable solutions from research to manufacturing

🔗 Learn more: https://hubs.ly/Q04dchcz0
Less variability. More confidence in your data.